Zacks Investment Research Lowers aTyr Pharma, Inc. (LIFE) to Hold
aTyr Pharma, Inc. (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
LIFE has been the topic of several other research reports. Piper Jaffray Companies assumed coverage on shares of aTyr Pharma in a research note on Thursday. They set an “overweight” rating and a $7.00 price objective on the stock. BMO Capital Markets set a $4.00 price objective on shares of aTyr Pharma and gave the stock a “hold” rating in a research note on Tuesday, August 15th. Finally, ValuEngine lowered shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $4.27.
Shares of aTyr Pharma (NASDAQ LIFE) traded up 8.93% during trading on Thursday, reaching $3.05. The company had a trading volume of 109,287 shares. aTyr Pharma has a 52-week low of $2.10 and a 52-week high of $4.45. The stock’s market capitalization is $72.71 million. The stock has a 50 day moving average of $3.05 and a 200 day moving average of $3.32.
aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.06. Equities research analysts forecast that aTyr Pharma will post ($2.18) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/09/07/zacks-investment-research-lowers-atyr-pharma-inc-life-to-hold.html.
In other news, Director Paul Schimmel purchased 94,336 shares of the company’s stock in a transaction on Thursday, August 31st. The shares were bought at an average price of $2.65 per share, for a total transaction of $249,990.40. Following the completion of the purchase, the director now owns 40,440 shares of the company’s stock, valued at $107,166. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John Mendlein purchased 37,736 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was purchased at an average price of $2.65 per share, for a total transaction of $100,000.40. The disclosure for this purchase can be found here. 33.30% of the stock is currently owned by company insiders.
An institutional investor recently raised its position in aTyr Pharma stock. Renaissance Technologies LLC raised its position in aTyr Pharma, Inc. (NASDAQ:LIFE) by 1.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,800 shares of the biotechnology company’s stock after purchasing an additional 700 shares during the quarter. Renaissance Technologies LLC owned about 0.16% of aTyr Pharma worth $136,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 46.66% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.